vs
GLAUKOS Corp（GKOS）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是GLAUKOS Corp的1.5倍（$219.9M vs $143.1M），Orthofix Medical Inc.净利率更高（-1.0% vs -93.4%，领先92.4%），GLAUKOS Corp同比增速更快（35.7% vs 2.0%），Orthofix Medical Inc.自由现金流更多（$16.8M vs $3.9M），过去两年GLAUKOS Corp的营收复合增速更高（29.3% vs 8.0%）
Glaukos Corp是一家专注于眼科领域的医疗科技企业，开发并商业化用于治疗青光眼、角膜疾病等眼部病症的微创手术器械、处方药物及消费级产品，主要市场覆盖北美、欧洲及亚太地区，为全球医院、眼科诊所及患者提供服务。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
GKOS vs OFIX — 直观对比
营收规模更大
OFIX
是对方的1.5倍
$143.1M
营收增速更快
GKOS
高出33.7%
2.0%
净利率更高
OFIX
高出92.4%
-93.4%
自由现金流更多
OFIX
多$12.9M
$3.9M
两年增速更快
GKOS
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $143.1M | $219.9M |
| 净利润 | $-133.7M | $-2.2M |
| 毛利率 | -1.1% | 71.1% |
| 营业利润率 | -97.7% | 0.2% |
| 净利率 | -93.4% | -1.0% |
| 营收同比 | 35.7% | 2.0% |
| 净利润同比 | -298.0% | 92.4% |
| 每股收益（稀释后） | $-2.34 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GKOSOFIX
| Q4 25 | $143.1M | $219.9M | ||
| Q3 25 | $133.5M | $205.6M | ||
| Q2 25 | $124.1M | $203.1M | ||
| Q1 25 | $106.7M | $193.6M | ||
| Q4 24 | $105.5M | $215.7M | ||
| Q3 24 | $96.7M | $196.6M | ||
| Q2 24 | $95.7M | $198.6M | ||
| Q1 24 | $85.6M | $188.6M |
净利润GKOSOFIX
| Q4 25 | $-133.7M | $-2.2M | ||
| Q3 25 | $-16.2M | $-22.8M | ||
| Q2 25 | $-19.7M | $-14.1M | ||
| Q1 25 | $-18.1M | $-53.1M | ||
| Q4 24 | $-33.6M | $-29.1M | ||
| Q3 24 | $-21.4M | $-27.4M | ||
| Q2 24 | $-50.5M | $-33.4M | ||
| Q1 24 | $-40.8M | $-36.0M |
毛利率GKOSOFIX
| Q4 25 | -1.1% | 71.1% | ||
| Q3 25 | 78.4% | 72.2% | ||
| Q2 25 | 78.3% | 68.7% | ||
| Q1 25 | 77.2% | 62.8% | ||
| Q4 24 | 72.9% | 69.0% | ||
| Q3 24 | 76.6% | 68.7% | ||
| Q2 24 | 76.4% | 67.8% | ||
| Q1 24 | 76.3% | 67.5% |
营业利润率GKOSOFIX
| Q4 25 | -97.7% | 0.2% | ||
| Q3 25 | -12.3% | -8.3% | ||
| Q2 25 | -18.3% | -7.9% | ||
| Q1 25 | -19.4% | -25.2% | ||
| Q4 24 | -27.2% | -5.3% | ||
| Q3 24 | -25.5% | -9.6% | ||
| Q2 24 | -31.3% | -12.5% | ||
| Q1 24 | -45.6% | -15.6% |
净利率GKOSOFIX
| Q4 25 | -93.4% | -1.0% | ||
| Q3 25 | -12.2% | -11.1% | ||
| Q2 25 | -15.8% | -6.9% | ||
| Q1 25 | -17.0% | -27.4% | ||
| Q4 24 | -31.8% | -13.5% | ||
| Q3 24 | -22.1% | -13.9% | ||
| Q2 24 | -52.8% | -16.8% | ||
| Q1 24 | -47.7% | -19.1% |
每股收益（稀释后）GKOSOFIX
| Q4 25 | $-2.34 | $-0.05 | ||
| Q3 25 | $-0.28 | $-0.57 | ||
| Q2 25 | $-0.34 | $-0.36 | ||
| Q1 25 | $-0.32 | $-1.35 | ||
| Q4 24 | $-0.56 | $-0.76 | ||
| Q3 24 | $-0.39 | $-0.71 | ||
| Q2 24 | $-1.00 | $-0.88 | ||
| Q1 24 | $-0.82 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $90.8M | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $656.2M | $450.0M |
| 总资产 | $893.5M | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GKOSOFIX
| Q4 25 | $90.8M | $82.0M | ||
| Q3 25 | $98.2M | $62.9M | ||
| Q2 25 | $100.8M | $65.6M | ||
| Q1 25 | $114.3M | $58.0M | ||
| Q4 24 | $169.6M | $83.2M | ||
| Q3 24 | $100.1M | $30.1M | ||
| Q2 24 | $68.1M | $26.4M | ||
| Q1 24 | $42.5M | $27.0M |
总债务GKOSOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M | ||
| Q1 24 | — | $118.2M |
股东权益GKOSOFIX
| Q4 25 | $656.2M | $450.0M | ||
| Q3 25 | $769.5M | $442.5M | ||
| Q2 25 | $765.1M | $458.3M | ||
| Q1 25 | $764.0M | $458.3M | ||
| Q4 24 | $766.9M | $503.1M | ||
| Q3 24 | $668.5M | $525.9M | ||
| Q2 24 | $665.2M | $546.0M | ||
| Q1 24 | $450.7M | $570.3M |
总资产GKOSOFIX
| Q4 25 | $893.5M | $850.6M | ||
| Q3 25 | $999.4M | $832.6M | ||
| Q2 25 | $987.0M | $837.2M | ||
| Q1 25 | $966.2M | $823.1M | ||
| Q4 24 | $974.8M | $893.3M | ||
| Q3 24 | $926.5M | $867.9M | ||
| Q2 24 | $919.7M | $882.0M | ||
| Q1 24 | $933.3M | $906.0M |
负债/权益比GKOSOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $6.8M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $3.9M | $16.8M |
| 自由现金流率自由现金流/营收 | 2.7% | 7.6% |
| 资本支出强度资本支出/营收 | 2.0% | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-22.5M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流GKOSOFIX
| Q4 25 | $6.8M | $27.7M | ||
| Q3 25 | $-10.1M | $12.4M | ||
| Q2 25 | $7.0M | $11.6M | ||
| Q1 25 | $-18.5M | $-18.4M | ||
| Q4 24 | $507.0K | $23.7M | ||
| Q3 24 | $-9.6M | $11.7M | ||
| Q2 24 | $-18.4M | $9.0M | ||
| Q1 24 | $-33.9M | $-18.6M |
自由现金流GKOSOFIX
| Q4 25 | $3.9M | $16.8M | ||
| Q3 25 | $-11.7M | $2.5M | ||
| Q2 25 | $5.8M | $4.5M | ||
| Q1 25 | $-20.5M | $-25.1M | ||
| Q4 24 | $-1.2M | $15.2M | ||
| Q3 24 | $-11.0M | $6.3M | ||
| Q2 24 | $-20.5M | $-360.0K | ||
| Q1 24 | $-34.8M | $-29.1M |
自由现金流率GKOSOFIX
| Q4 25 | 2.7% | 7.6% | ||
| Q3 25 | -8.8% | 1.2% | ||
| Q2 25 | 4.7% | 2.2% | ||
| Q1 25 | -19.2% | -13.0% | ||
| Q4 24 | -1.2% | 7.0% | ||
| Q3 24 | -11.4% | 3.2% | ||
| Q2 24 | -21.4% | -0.2% | ||
| Q1 24 | -40.7% | -15.4% |
资本支出强度GKOSOFIX
| Q4 25 | 2.0% | 4.9% | ||
| Q3 25 | 1.2% | 4.8% | ||
| Q2 25 | 0.9% | 3.5% | ||
| Q1 25 | 1.8% | 3.5% | ||
| Q4 24 | 1.6% | 4.0% | ||
| Q3 24 | 1.5% | 2.7% | ||
| Q2 24 | 2.2% | 4.7% | ||
| Q1 24 | 1.1% | 5.6% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GKOS
| Glaucoma | $86.4M | 60% |
| Other | $35.1M | 25% |
| Corneal Health | $21.6M | 15% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
